Vietnam Graft-versus-Host Disease (GvHD) Therapeutics Market Report 2023 to 2030

Vietnam Graft-versus-Host Disease (GvHD) Therapeutics Market Analysis

$ 3999

The Vietnam GvHD Therapeutics Market was valued at $12.5 Mn in 2023 and is predicted to grow at a CAGR of 8.33% from 2023 to 2030, to $21.89 Mn by 2030. Such growth has been driven by factors like improvement in health infrastructure, better research, growing awareness, and medical tourism. The key players in this competitive market are Incyte, MaaT, Mesoblast, Kadmon, Jazz, Neovii, and Novartis among others.

ID: IN10VNPH571 CATEGORY: Pharmaceuticals GEOGRAPHY: Vietnam AUTHOR: Hetvi Kothari

Buy Now

Vietnam Graft-versus-Host Disease (GvHD) Therapeutics Market Executive Summary

The Vietnam GvHD Therapeutics Market was valued at $12.5 Mn in 2023 and is predicted to grow at a CAGR of 8.33% from 2023 to 2030, to $21.89 Mn by 2030.

Graft-versus-host disease (GvHD) is a serious condition that can occur after a transplant when the donor's immune cells attack the recipient's body. The immune system's blood cells are crucial in defending the body against infections by targeting and eliminating foreign invaders, such as bacteria and viruses, that are recognized as threats due to their non-host origin. This recognition process is facilitated by Human Leukocyte Antigens (HLAs), proteins that help differentiate self from non-self-cells. When there is a significant mismatch in HLAs between the donor and recipient, the donor's blood cells may perceive the recipient's cells as foreign and launch an attack, resulting in GvHD. This disease can present in acute or chronic forms, with symptoms such as nausea, rash, jaundice, abdominal cramping, hair loss, and dry mouth. Treatment for GvHD often involves immunosuppressive medications, chemotherapy, and antifungal and antiviral drugs, among other therapeutic approaches.

The treatments get expensive every year by 3.2% due to medical inflation. Various novel therapies are now available in the Vietnam GvHD market like blinatumomab and Polatuzumab Vedotin (Polivy). Along with growth drivers, there are also some restraints in the market. A complex regulatory environment, high treatment costs, and market competition are some such factors.

Market Dynamics

Market Growth Drivers

Improvement in Health Infrastructure: Vietnam has been investing heavily in expanding and modernizing its healthcare facilities. Major hospitals in cities like Hanoi and Ho Chi Minh City are being upgraded to include state-of-the-art equipment and specialized units for cancer and hematology, which are essential for the treatment of GvHD. This would be helpful to serve more patients, driving the market.

Better Research: The Vinmec Research Institute of Stem Cell and Gene Technology is actively involved in research and clinical trials. The results and learning from those researches are made available to professionals, clients, skilled workers, and hospitals to cater to needs. Better research can drive market growth by developing more effective treatments, enhancing diagnostic techniques, and improving patient outcomes.

Medical Tourism Hub: The Vietnamese hospitals attract patients from various neighboring countries due to their effective and cost-efficient treatments. This provides additional revenue apart from local patients. The medical tourism revenue has been around $2 Bn annually. Medical tourism can drive leukemia market growth by attracting international patients seeking advanced treatments and specialized care not available in their home countries, thereby increasing demand.

Market Restraints

Complex Regulatory Environment: Pharma companies may face various regulatory challenges and stringent requirements to be followed which can delay the launch of drugs. The approval process takes 2 years or sometimes even more. Taking approvals from the Health Science Authority can be a bit tedious. These hurdles may limit innovation and market competitiveness, ultimately impeding patient access to cutting-edge therapies.

High Treatment Costs: Treatments like biologics and CAR-T cell therapy can cost around $350,000 in Vietnam. There are insurances available, but the expenses are paid out of pocket for like 20% of costs. The recognition as a medical hub may reduce some costs, but novel treatments are still not affordable by many. Lack of affordability restricts growth.

Market Competition: There are around 30 competitors in the market. That can build up pressure on prices. The new entrants may have to face high barriers, limiting market growth. The small patient pool poses a limitation to market growth for GvHD treatments.

Regulatory Landscape and Reimbursement Scenario

The regulatory landscape in Vietnam includes several key entities and regulations. The Ministry of Health (MOH) is accountable for devising policies and supervising healthcare services. Drug Administration of Vietnam (DAV) is the primary regulatory body for regulating and licensing cancer-related drugs across the country.

The regulatory landscape in Vietnam has several key laws and circulars that govern the pharmaceutical industry, clinical trials, and disease management. It takes 12-24 months for drug review.

Vietnam’s national health insurance scheme ensures coverage for a wide range of treatments except for some novel therapies. Approximately, 90% of people are covered under these insurances. Around 20% of expenses are done out of pocket.

Competitive Landscape

Here are some of the major key players in the Vietnam GvHD Therapeutics Market

Novartis
Takeda
MaaT
Kadmon
Jazz
Neovii
Incyte
Mesoblast
Pfizer
Sanofi

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Vietnam Graft-versus-Host Disease (GvHD) Therapeutics Market Segmentation

By Gender

Male
Female

By Age

Children
Adults
Senior Citizens

By Treatment Type

Corticosteroids
Immunosuppressant
mTOR inhibitors
Monoclonal inhibitors
Tyrosine kinase inhibitors
Others

By Disease Type

Acute
Chronic

By Route of Administration

Oral
Intravenous
Topical

By Distribution Channel

Online channel
Retail Stores
Hospitals

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.